Search

everythinglearnresearchcommunity

for

Search:↓

A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.

The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks about Redensyl's effectiveness, questioning if it's another ineffective remedy.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User questions effectiveness of Redensyl.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

User wants to buy TO hair serum with redensyl but found a website not listing redensyl in ingredients. No specific treatments mentioned.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.

The conversation is about someone's three-year experience with irregular derma rolling, Minoxidil, and Redensyl for hair loss, hoping to thicken areas with fine hair.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

Serevelle is being considered for hair loss due to menopause, but its effectiveness is unclear. Minoxidil and hormone management are suggested alternatives.

Finasteride and Nizoral shampoo with Ketoconazole are used for hair loss treatment. Liquid Chromatography–Mass Spectrometry (LC-MS) is recommended over Enzyme-Linked Immunosorbent Assay (ELISA) for more accurate DHT testing.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.